US5498524A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of testing for heart failure risk
Assignee: Medinnova SF
•
Filing: 1994-01-25
•
Granted: 1996-03-12
•
Expires: 2014-01-25
Abstract
Abstract The peptide N-terminal pro-ANF, which is present in body fluids such as plasma, has been found to be an effective predictor of heart failure and the invention provides prediction and screening methods based upon in vitro assaying of N-terminal pro-ANF in body fluids.
Inventors
- 👤 Christian Hall
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 13:55
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/74; G01N2333/00; G01N2333/435; G01N2333/575; G01N2333/58; Y; Y10; Y10S; Y10S436/00; Y10S436/811
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
58 words
A method of testing for heart failure risk in an asymptomatic patient, which comprises contacting a body fluid sample from the asymptomatic patient with an antibody which specifically binds to N-terminal Pro-ANF and detecting the formation of an immune complex by immunoassay, and comparing the peptide level thus obtained to control levels as an indication of said risk.
Claim 2
Independent Claim
58 words
A method of testing for heart failure risk in an asymptomatic patient, which comprises contacting a body fluid sample from the asymptomatic patient with an antibody which specifically binds to N-terminal Pro-ANF and detecting the formation of an immune complex by immunoassay, and comparing the peptide level thus obtained to control levels as an indication of said risk.
Claim 3
Independent Claim
61 words
A method of screening asymptomatic patients, either for risk of developing heart failure, or lack thereof, which comprises contacting a body fluid sample from the asymptomatic patient with an antibody which specifically binds to N-terminal Pro-ANF and detecting the formation of an immune complex by immunoassay, and assessing the patient's risk of developing heart failure upon the basis of said levels.
Claim 4
Independent Claim
61 words
A method of screening asymptomatic patients, either for risk of developing heart failure, or lack thereof, which comprises contacting a body fluid sample from the asymptomatic patient with an antibody which specifically binds to N-terminal Pro-ANF and detecting the formation of an immune complex by immunoassay, and assessing the patient's risk of developing heart failure upon the basis of said levels.
Claim 5
Dependent Claim
37 words
A method as claimed in claim 1 or claim 2 wherein said human is selected from humans over 70 years of age, humans exhibiting hypertension and humans having or having previously had a form of heart disease.
Claim 6
Dependent Claim
15 words
A method as claimed in claim 1 or 2 wherein said body fluid comprises plasma.
Claim 7
Dependent Claim
30 words
A method as claimed in claim 4 wherein a plasma level of higher than 1500 pmols N-terminal pro-ANF/L plasma is taken as indicative of risk of development of heart failure.
Claim 8
Dependent Claim
16 words
A method as claimed in claim 1 or claim 2 wherein said body fluid comprises plasma.
Claim 9
Dependent Claim
30 words
A method as claimed in claim 6 wherein a plasma level of higher than 1500 pmols N-terminal pro-ANF/l plasma is taken as indicative of risk of development of heart failure.
Claim 10
Dependent Claim
18 words
A method as claimed in claim 1 or claim 2, wherein the level of N-terminal pro-ANF is determined.
Claim 11
Dependent Claim
22 words
A method as claimed in claim 1 or claim 2, wherein an immunoassay is performed using an antibody raised against N-terminal pro-ANF.
Claim 12
Dependent Claim
61 words
The method of claim 1 wherein said contacting step is conducted using components from a kit comprising (a) an antibody which specifically binds to N-terminal pro-ANF, and at least one of the following; (b) a labeled sample of N-terminal pro-ANF; (c) an antibody, as defined in (a), in non-immobilized form; or (d) a labeled secondary antibody specific to said antibody (c).
Claim 13
Dependent Claim
61 words
The method of claim 2 wherein said contacting step is conducted using components from a kit comprising (a) an antibody which specifically binds to N-terminal pro-ANF, and at least one of the following; (b) a labeled sample of N-terminal pro-ANF; (c) an antibody, as defined in (a), in non-immobilized form; or (d) a labeled secondary antibody specific to said antibody (c).
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-03-12 | 1999-09-11 | 2000-03-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-03-12 | 2003-09-11 | 2004-03-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-03-12 | 2007-09-11 | 2008-03-12 | $7700.00 | Window Closed / Lapsed |